Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease

ObjectiveIn this study, we assessed plasma biomarkers to identify cognitive impairment in Parkinson’s disease (PD) patients by applying ultra-sensitive immunomagnetic reduction-based immunoassay (IMR).MethodsThe study enrolled 60 PD patients and 28 age- and sex-matched normal controls. Complete cogn...

Full description

Bibliographic Details
Main Authors: Nai-Ching Chen, Hsiu-Ling Chen, Shau-Hsuan Li, Yen-Hsiang Chang, Meng-Hsiang Chen, Nai-Wen Tsai, Chiun-Chieh Yu, Shieh-Yueh Yang, Cheng-Hsien Lu, Wei-Che Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnagi.2020.00112/full
id doaj-3c102b1b2bea4f0f825267cc59324028
record_format Article
spelling doaj-3c102b1b2bea4f0f825267cc593240282020-11-25T02:26:27ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652020-04-011210.3389/fnagi.2020.00112509774Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s DiseaseNai-Ching Chen0Hsiu-Ling Chen1Shau-Hsuan Li2Yen-Hsiang Chang3Meng-Hsiang Chen4Nai-Wen Tsai5Chiun-Chieh Yu6Shieh-Yueh Yang7Cheng-Hsien Lu8Wei-Che Lin9Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Oncology and Hematology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Nuclear Medicine, Chang Gung University College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanMagQu Co., Ltd., New Taipei City, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanObjectiveIn this study, we assessed plasma biomarkers to identify cognitive impairment in Parkinson’s disease (PD) patients by applying ultra-sensitive immunomagnetic reduction-based immunoassay (IMR).MethodsThe study enrolled 60 PD patients and 28 age- and sex-matched normal controls. Complete cognitive function assessments were performed on participants using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating. PD patients with an MMSE score of ≦26 were defined as having cognitive impairment. Meanwhile, a 99mTc-TRODAT-1 scan was performed and plasma levels of Aβ-40, Aβ-42, T-tau, and α-synuclein were evaluated using IMR, subsequent correlation analyses were then performed.ResultsCompared with normal adults, PD patients have higher plasma levels of α-synuclein and T-tau, and a lower level of Aβ-40 (p < 0.05). Plasma levels of α-synuclein (r = −0.323, p = 0.002), Aβ-40 (r = 0.276, p = 0.01), and T-tau (r = −0.322, p = 0.002) are significantly correlated with MMSE scores. The TRODAT scan results, including visual inspection and quantification, revealed significant correlations between Aβ-40 and PD. Multiple regression analysis showed that the plasma levels of Aβ-40 (OR = 0.921, 95% CI = 0.879–0.962), α-synuclein (OR = 3.016, 95% CI = 1.703–5.339), and T-tau (OR = 1.069, 95% CI = 1.026–1.115) were independently associated with PD patients with cognitive impairment. The cutoff values for predicting cognitive deficits in PD patients were 45.101 pg/ml of Aβ-40, (Area under curve (AUC) = 0.791), 0.389 pg/ml of α-synuclein, (AUC = 0.790), and 30.555 pg/ml of T-tau (AUC = 0.726).ConclusionPlasma levels of α-synuclein, Aβ-40, and T-tau are potential biomarkers to detect cognitive impairment in PD patients.https://www.frontiersin.org/article/10.3389/fnagi.2020.00112/fullParkinson’s diseaseimmunomagnetic reductionplasma biomarkerplasma Aβ-40Aβ-42T-tau
collection DOAJ
language English
format Article
sources DOAJ
author Nai-Ching Chen
Hsiu-Ling Chen
Shau-Hsuan Li
Yen-Hsiang Chang
Meng-Hsiang Chen
Nai-Wen Tsai
Chiun-Chieh Yu
Shieh-Yueh Yang
Cheng-Hsien Lu
Wei-Che Lin
spellingShingle Nai-Ching Chen
Hsiu-Ling Chen
Shau-Hsuan Li
Yen-Hsiang Chang
Meng-Hsiang Chen
Nai-Wen Tsai
Chiun-Chieh Yu
Shieh-Yueh Yang
Cheng-Hsien Lu
Wei-Che Lin
Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
Frontiers in Aging Neuroscience
Parkinson’s disease
immunomagnetic reduction
plasma biomarker
plasma Aβ-40
Aβ-42
T-tau
author_facet Nai-Ching Chen
Hsiu-Ling Chen
Shau-Hsuan Li
Yen-Hsiang Chang
Meng-Hsiang Chen
Nai-Wen Tsai
Chiun-Chieh Yu
Shieh-Yueh Yang
Cheng-Hsien Lu
Wei-Che Lin
author_sort Nai-Ching Chen
title Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
title_short Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
title_full Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
title_fullStr Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
title_full_unstemmed Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
title_sort plasma levels of α-synuclein, aβ-40 and t-tau as biomarkers to predict cognitive impairment in parkinson’s disease
publisher Frontiers Media S.A.
series Frontiers in Aging Neuroscience
issn 1663-4365
publishDate 2020-04-01
description ObjectiveIn this study, we assessed plasma biomarkers to identify cognitive impairment in Parkinson’s disease (PD) patients by applying ultra-sensitive immunomagnetic reduction-based immunoassay (IMR).MethodsThe study enrolled 60 PD patients and 28 age- and sex-matched normal controls. Complete cognitive function assessments were performed on participants using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating. PD patients with an MMSE score of ≦26 were defined as having cognitive impairment. Meanwhile, a 99mTc-TRODAT-1 scan was performed and plasma levels of Aβ-40, Aβ-42, T-tau, and α-synuclein were evaluated using IMR, subsequent correlation analyses were then performed.ResultsCompared with normal adults, PD patients have higher plasma levels of α-synuclein and T-tau, and a lower level of Aβ-40 (p < 0.05). Plasma levels of α-synuclein (r = −0.323, p = 0.002), Aβ-40 (r = 0.276, p = 0.01), and T-tau (r = −0.322, p = 0.002) are significantly correlated with MMSE scores. The TRODAT scan results, including visual inspection and quantification, revealed significant correlations between Aβ-40 and PD. Multiple regression analysis showed that the plasma levels of Aβ-40 (OR = 0.921, 95% CI = 0.879–0.962), α-synuclein (OR = 3.016, 95% CI = 1.703–5.339), and T-tau (OR = 1.069, 95% CI = 1.026–1.115) were independently associated with PD patients with cognitive impairment. The cutoff values for predicting cognitive deficits in PD patients were 45.101 pg/ml of Aβ-40, (Area under curve (AUC) = 0.791), 0.389 pg/ml of α-synuclein, (AUC = 0.790), and 30.555 pg/ml of T-tau (AUC = 0.726).ConclusionPlasma levels of α-synuclein, Aβ-40, and T-tau are potential biomarkers to detect cognitive impairment in PD patients.
topic Parkinson’s disease
immunomagnetic reduction
plasma biomarker
plasma Aβ-40
Aβ-42
T-tau
url https://www.frontiersin.org/article/10.3389/fnagi.2020.00112/full
work_keys_str_mv AT naichingchen plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT hsiulingchen plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT shauhsuanli plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT yenhsiangchang plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT menghsiangchen plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT naiwentsai plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT chiunchiehyu plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT shiehyuehyang plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT chenghsienlu plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
AT weichelin plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease
_version_ 1724847007667847168